Profusa, Inc. (PFSA): Results of Operations and Financial Condition
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001859807 0001859807 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The filing signals the first public release of the quarter's performance, but the lack of disclosed metrics limits immediate trading decisions.
Market read
Primary disclosure of results, but without quantitative data the market impact is expected to be modest.
What to watch
Potential upcoming FDA submissions or partnership announcements not disclosed in the filing could drive future moves.
Background
Profusa, Inc. (PFSA) is a Nasdaq‑listed biotech company that filed an 8‑K to announce its quarterly results.
Ticker impact
SEC Form 8‑K filed on Aug 20 2026 announcing Profusa's quarterly results for the quarter ended June 30 2026.
Modest move expected as investors await detailed numbers from the press release.
The filing is a primary source but lacks quantitative data, so the market reaction will likely be muted until the press release is reviewed.
Market effects
Provides a data point for the biotech/diagnostics sector, but no material insight without numbers.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact due to the company's small market cap.
Counterpoint
Without numbers, the filing could be a smoke screen; investors might short on the expectation of weak results.
Key entities
- CompanyProfusa, Inc.
Issuer of the 8‑K filing.
- ExecutiveFred Knechtel
Chief Financial Officer who signed the filing.